Clinical trial · no report yet · Phase 1/Phase 2
NCT06162221
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
- NCT06162221 ↗
- Recruiting
- Revolution Medicines, Inc.
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 2 | |
| Bluesky threads | 1 |
The trial
ClinicalTrials.gov- Official title
- A Platform Study of RAS(ON) Inhibitors in Patients With RAS-Mutated Non-Small Cell Lung Cancer (NSCLC)
- Phase
- Phase 1/Phase 2
- Status
- Recruiting
- Conditions
- Non-Small Cell Lung Cancer, NSCLC; KRAS, NRAS, HRAS-mutated NSCLC; KRAS G12C-mutated Solid Tumors, Lung Cancer; Lung Cancer Stage IV, Advanced Solid Tumor, Cancer; RAS G12D-mutated NSCLC
- Interventions
- RMC-6291; RMC-6236; Pembrolizumab; Cisplatin; Carboplatin; Pemetrexed; RMC-9805
- Arms
- Subprotocol A: KRAS G12C-Mutated Solid Tumors · Experimental
- Subprotocol B: RAS-mutated NSCLC · Experimental
- Subprotocol C: RAS G12D-mutated NSCLC · Experimental
- Subprotocol D: RAS G12D-mutated NSCLC · Experimental
- Enrollment
- 616 (estimated)
- Primary outcomes
- Adverse events
- Dose limiting toxicities
- Sponsor
- Revolution Medicines, Inc.
- Start
- Jan 18, 2024
- Primary completion
- Jun 2027 (estimated)
- Results posted
- No
- Registry record
- NCT06162221 · updated Oct 19, 2026
Publications
linked from the registry- Cregg J, Edwards AV, Chang S, Lee BJ, Knox JE, Tomlinson ACA, Marquez A, Liu Y, Freilich R, Aay N, Wang Y, Jiang L, Jiang J, Wang Z, Flagella M, Wildes D, Smith JAM, Singh M, Wang Z, Gill AL, Koltun ES. Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers. J Med Chem. 2025 Mar 27;68(6):6064-6083. doi: 10.1021/acs.jmedchem.4c02314. Epub 2025 Mar 8. PubMed 40056080